Education
About Us
Working with TipRanks
Follow Us
Poolbeg Pharma Ltd. (GB:POLB)
LSE:POLB
POLB Stock Chart & Stats
3.55p
0.24p(5.04%)
At close: 4:00 PM EST
3.55p
0.24p(5.04%)
Day’s Range― - ―
52-Week Range2.25p - 5.20p
Previous CloseN/A
Volume846.29K
Average Volume (3M)1.12M
Market Cap
£33.14M
Enterprise Value23.18M
Total Cash (Recent Filing)£9.96M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding705,103,760
10 Day Avg. Volume836,211
30 Day Avg. Volume1,116,415
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.82
Price to Sales (P/S)0.00
P/FCF Ratio-7.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure materially reduces solvency and interest-rate risk for a clinical-stage biotech. This durable strength preserves flexibility to raise equity or structure partnership deals without debt covenants, improving resilience through development cycles.
Human Challenge Trial ApproachUsing human challenge trials to generate early clinical proof reduces time, cost and uncertainty for infectious-disease assets. That structural de-risking can accelerate proof-of-concept milestones, making programs more attractive to partners and improving chances of timely licensing.
Partner-led Monetization ModelA business model focused on advancing to value-inflection points and out-licensing is capital-efficient and avoids the costs of commercial infrastructure. Over time this allows focused R&D spending and scalable value capture through deals and royalties rather than building a sales organization.
Bears Say
No Revenue, Widening LossesSustained lack of product revenue and expanding net losses mean the company must rely on external funding or partner deals to progress assets. Persistent losses erode capital, raise dilution risk, and constrain the firm’s ability to independently advance multiple programs over the medium term.
Rising Cash Burn And Weak Cash GenerationConsistently negative operating and free cash flows with rising burn create structural funding pressure. Because cash outflows closely track accounting losses, the company will repeatedly need financing or deal milestones to sustain R&D cadence, risking program delays if funding gaps occur.
Eroding Equity And Asset BaseSubstantial declines in shareholders' equity and total assets indicate cumulative losses have materially weakened the capital base. This reduces financial cushion, may impair negotiating leverage with partners or licensors, and increases vulnerability to adverse clinical or funding events.
Poolbeg Pharma Ltd. News
POLB FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest share price was 2.25p and its highest was 5.20p in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Poolbeg Pharma Ltd.’s market cap is £33.14M.
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Feb 26, 2026 which is in 9 days.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Sep 29, 2025. The company reported -0.004p earnings per share for the quarter, the consensus estimate of -0.004p by 0p.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 705,103,760 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -0.004p in its last earnings report, expectations of -0.004p. Following the earnings report the stock price went up 2.564%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in GB:POLB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Open Orphan Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---